ArticlePloS one2025
PrEP knowledge and perceptions among women living in North Carolina public housing communities.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PrEP4Her: Evaluating the Reach, Adoption, Preliminary Effectiveness and Fidelity of a Multi-Component Hybrid Type 3 Trial Designed to Increase PrEP Prescriptions for Black Women Receiving Gynaecologic Care in a University-Affiliated Women's Health Setting in the United States South.Journal of the International AIDS Society · 2026Trial
- Assessing the Feasibility and Acceptability of a Mobile Medical Unit Program-(IFE4Her) to Enhance PrEP Awareness and Access Among Cis-gender Women in Low-Income Southeastern Communities: A Pilot Study.AIDS and behavior · 2026Article
- HIV/STI Prevention Strategies During COVID-19 Among PrEP-Eligible Cisgender Women in New York State: A Qualitative Analysis.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Women in low-income communities are disproportionately affected by HIV yet have been largely left out of efforts to raise awareness about pre-exposure prophylaxis (PrEP). To inform future awareness campaigns, we assessed women's current knowledge of and attitudes toward PrEP. We surveyed 184 women living in public housing communities in North Carolina regarding PrEP knowledge, attitudes, and perceived norms, as well as reported HIV-associated factors and perceived HIV acquisition chances. 38 women participated in eight focus group discussions (FGDs) addressing personal and community PrEP perceptions. Survey participants were 46 years old on average, and 86% identified as Black/African American. Only 35% had heard of PrEP, yet, after being told what it was, 61% said they probably or definitely would take PrEP in the next 6 months. Most women believed that if they decided to take PrEP, their partner (72%) or their family (66%) would approve. When asked about the importance of factors influencing their interest in PrEP, women most frequently rated possible side effects as important or very important (76%), followed by cost considerations (67% for cost of PrEP, 74% for cost of clinic visits and labs). In the FGDs, women had limited PrEP knowledge, but several had heard of PrEP from television commercials, which gave them the impression that PrEP was only for men. Women were concerned about potential side effects, interactions with other medications, safety during pregnancy, and the burden of daily dosing. Most FGD participants expressed generally positive attitudes toward PrEP, but some thought other women would be uninterested due to low perceived chances of HIV acquisition. Overall, these results suggest that while few women had previously heard of PrEP, most were interested in PrEP after receiving information about it and perceived positive community attitudes toward PrEP. Our findings indicate the importance of community-based PrEP communication that speaks to cisgender women, provides information on side effects, and offers destigmatized messaging regarding reasons for HIV prevention for women to consider.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.